STAT+: Breast cancer pill from AstraZeneca misses mark in pivotal trial
Phase 3negativeNegative
AI Analysis
Summary
AstraZeneca's breast cancer pill failed to meet primary efficacy endpoints in a pivotal clinical trial. The negative result may restrict the drug's potential clinical use and market opportunities.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Not Met
Outcome Details
Failed to improve outcomes in pivotal trial
Importance:8/10
Sentiment:
-0.80
oncologybreast cancerpivotal trialtrial failure
Related Companies
Read the original article
Published by STAT News on September 12, 2026 7:09 AM